Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBPNASDAQ:ELEVNASDAQ:EYENNASDAQ:LGVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.38+11.9%$0.00$0.22▼$15.80$18.85M0.918.19 million shs2.56 million shsELEVElevation Oncology$0.32+4.9%$0.32$0.22▼$3.74$18.95M1.431.38 million shs399,164 shsEYENEyenovia$4.88+55.4%$1.36$0.85▼$124.80$14.07M0.76718,124 shs38.84 million shsLGVNLongeveron$1.23+4.2%$1.42$0.77▼$6.40$18.36M0.222.96 million shs91,064 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+11.91%+38,049,900.00%+38,049,900.00%+38,049,900.00%+38,049,900.00%ELEVElevation Oncology+4.85%+4.82%-3.79%-37.37%-91.40%EYENEyenovia+55.41%+187.06%+356.07%+206.92%-92.08%LGVNLongeveron+4.24%-0.81%-17.45%-18.54%+12.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AELEVElevation Oncology2.3862 of 5 stars4.22.00.00.00.81.70.6EYENEyenovia0.7633 of 5 stars1.05.00.00.00.60.01.3LGVNLongeveron3.2082 of 5 stars3.65.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/AELEVElevation Oncology 2.30Hold$3.39958.37% UpsideEYENEyenovia 2.00Hold$2.00-59.02% DownsideLGVNLongeveron 3.25Buy$8.67604.61% UpsideCurrent Analyst Ratings BreakdownLatest EYEN, ASBP, LGVN, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025ELEVElevation OncologyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AEYENEyenovia$67.06K209.79N/AN/A$16.32 per share0.30LGVNLongeveron$2.23M8.25N/AN/A$2.68 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire BiopharmaN/AN/A0.00∞N/AN/AN/AN/AN/AELEVElevation Oncology-$45.70M-$0.82N/AN/AN/AN/A-59.73%-40.05%8/5/2025 (Estimated)EYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)LGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%8/13/2025 (Estimated)Latest EYEN, ASBP, LGVN, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/15/2025Q1 2025ELEVElevation Oncology-$0.20-$0.24-$0.04-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/AN/AN/AELEVElevation Oncology0.4517.7717.77EYENEyenovia0.580.740.55LGVNLongeveronN/A7.677.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%ELEVElevation Oncology83.70%EYENEyenovia25.84%LGVNLongeveron10.01%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%ELEVElevation Oncology8.10%EYENEyenovia7.10%LGVNLongeveron11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 millionN/AN/AELEVElevation Oncology4059.22 million54.33 millionOptionableEYENEyenovia402.88 million1.29 millionOptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableEYEN, ASBP, LGVN, and ELEV HeadlinesRecent News About These CompaniesLongeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in StockJune 3, 2025 | insidertrades.comHere's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash WiselyMay 29, 2025 | finance.yahoo.comLongeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International ConventionMay 22, 2025 | nasdaq.comLongeveron Inc.May 21, 2025 | marketwatch.comLongeveron® to Attend BIO International Convention 2025May 20, 2025 | globenewswire.comLongeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award RecipientMay 12, 2025 | globenewswire.comLongeveron Inc. (LGVN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comLGVN Entering Crucial Period in Great ShapeMay 9, 2025 | msn.comRoth MKM Remains a Buy on Longeveron (LGVN)May 9, 2025 | theglobeandmail.comLongeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comLongeveron® Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finance.yahoo.comLongeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025May 2, 2025 | globenewswire.comLongeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025April 23, 2025 | finance.yahoo.comLongeveron Inc. CEO Shares 2024 Progress and Strategic Goals for 2025 in Shareholder LetterApril 22, 2025 | quiverquant.comLongeveron Stock Short Interest Report | NASDAQ:LGVN | BenzingaApril 18, 2025 | benzinga.comLGVN Announces Positive Alzheimer’s NewsMarch 20, 2025 | msn.comLongeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s DiseaseMarch 20, 2025 | finance.yahoo.comLongeveron (LGVN) Receives a Buy from Roth MKMMarch 20, 2025 | markets.businessinsider.comRoth MKM Keeps Their Buy Rating on Longeveron (LGVN)March 12, 2025 | markets.businessinsider.comLongeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's DiseaseMarch 11, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEYEN, ASBP, LGVN, and ELEV Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.38 +0.04 (+11.91%) As of 06/6/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Elevation Oncology NASDAQ:ELEV$0.32 +0.01 (+4.85%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-0.59%) As of 06/6/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Eyenovia NASDAQ:EYEN$4.88 +1.74 (+55.41%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.46 -0.42 (-8.50%) As of 06/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Longeveron NASDAQ:LGVN$1.23 +0.05 (+4.24%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.41%) As of 06/6/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
